Few Indian statutes have died as strangely as SICA 1985, the Sick Industrial Companies (Special Provisions) Act. Parliament passed the Act that repealed it in 2003, and the President assented to that repealing Act on 1 January 2004. The repeal then waited. For thirteen years the supposedly repealed statute continued to run the entire law of industrial sickness in India: companies kept filing references under it, its tribunal kept hearing them, and its famous stay provision kept freezing the claims of banks, tax authorities and landlords against hundreds of failing firms. When the end finally came on 1 December 2016, the repealing Act had itself been amended, before spending a single day in force, by the Insolvency and Bankruptcy Code of 2016, the very statute whose arrival made the repeal possible. A law had been repealed, in other words, by a successor that did not exist when the repeal was enacted, and the repeal could not be switched on until the successor was ready to receive the cases the old regime would leave behind.

This article reconstructs that whole arc. It explains what the Sick Industrial Companies (Special Provisions) Act set out to do and how its machinery actually worked in the sections: the balance-sheet definition of sickness, the compulsory reference to the Board for Industrial and Financial Reconstruction, the inquiry, the sanctioned scheme, and the Section 22 stay that suspended nearly every form of enforcement against a sick company. It then examines why the design failed on its own terms, how three successive attempts to replace it were drafted, and why the repeal enacted in 2003 could not commence until December 2016. The argument running through the account is that the thirteen-year gap was not simple administrative neglect. It was a case of repeal by dependency: a repeal whose commencement was hostage to the existence of a replacement tribunal, and that tribunal spent more than a decade trapped in litigation about its own constitution. Telling that kind of gap apart from deliberate inaction matters, because the two failures have different causes and deserve different verdicts.

Why SICA 1985 had to end

By the time Parliament turned to repeal at the start of the century, the case against the sickness regime had been assembled three times over, by three different kinds of evidence. The first was the regime’s own arithmetic. The Eradi Committee, chaired by Justice V. Balakrishna Eradi and reporting on 31 July 2000, recorded that of the 3,068 cases referred to the Board for Industrial and Financial Reconstruction between 1987 and 2000, all but 1,062 had been disposed of, and among those disposed of, 264 companies had been revived, 375 were under negotiation for revival, 741 had been recommended for winding up and 626 had been dismissed as not maintainable. A rescue tribunal that revived 264 companies in thirteen years, while recommending the burial of nearly three times as many and leaving more than a thousand files open, had failed the purpose written into its own preamble. The Eradi Committee said the Act’s effectiveness had been severely undermined by enormous delays, and it recommended repeal outright.

The second kind of evidence was doctrinal. The heart of the regime, Section 22, suspended proceedings for winding up, execution, distress, the appointment of a receiver, and suits for the recovery of money or the enforcement of security against a company under inquiry, except with the consent of the Board or its appellate authority. In a rescue statute some such stay is defensible, even necessary: assets cannot be reassembled into a viable business while individual creditors dismantle them. What the record showed, however, was a stay that began almost automatically on the filing of a reference, lasted for years while inquiries and schemes drifted, and left the promoters whose management had produced the sickness in undisturbed control of the company throughout. Lenders who had financed plant and working capital found their security unenforceable; governments found their tax dues unrecoverable; and the company’s own board, which alone could start the process in the ordinary way, acquired a powerful incentive to start it late for itself and early as a shield. The moratorium designed to protect a convalescent became, in the standard criticism levelled by bankers and by the Goswami Committee a decade earlier, a shelter for defaulters.

The third kind of evidence was comparative and conceptual. The Goswami Committee of 1993, chaired by Dr Omkar Goswami, had already argued that the statute defined sickness in the wrong way and at the wrong moment: it recognised a company as sick only after its entire net worth had been destroyed, which in accounting terms is very late in a decline, and it organised rescue around balance-sheet repair negotiated under official supervision rather than around the simple commercial fact of default. A legal order that waits for complete erosion before intervening, and then intervenes by freezing the creditors rather than by changing the management or the capital structure, had the sequence backwards. The insolvency reformers who eventually drafted the Bankruptcy Code inverted both choices. Their statute would be triggered by default, would hand control to creditors on admission, and would treat revival as one outcome among others rather than as the presumptive goal. For that inversion to displace the old law, however, the old law first had to be removed, and removing it turned out to be the slowest step of all.

Against these three bodies of evidence stood one honest counterweight, which any fair account of the repeal must carry. The Board for Industrial and Financial Reconstruction operated in the part of the economy where liquidation was not merely a legal outcome but a political event. A large textile mill or steel plant was frequently the dominant employer of a town, and its closure meant the concentrated loss of thousands of jobs in a single district, with consequences no state government wished to own. The Board’s members, directed by the statute to attempt revival wherever revival was practicable, were being asked to absorb a decision that elected governments, company boards and lending institutions were each unwilling to take themselves. Some part of its delay was therefore the delay of the political system working through a tribunal. That qualification explains the Board’s history; it does not rescue the design. A statute that places an impossible decision on a tribunal and then gives the failing company’s promoters a stay against their creditors while the tribunal deliberates has not solved the political problem. It has converted it into a subsidy, paid by lenders and suppliers, to the very management under examination.

A fourth body of evidence, quieter in the debates but decisive in the timing, was fiscal. The subsidy the shelter distributed was not paid from any budget line that a legislature voted on. It accumulated on the balance sheets of public sector banks and financial institutions as loans that could neither be serviced nor written off, and it accumulated against the state itself as tax dues, provident fund contributions and statutory payments that Section 22 placed beyond recovery while a case was pending, as the Corromandal Pharmaceuticals litigation over sales tax dues illustrates. So long as accounting conventions allowed such assets to be carried at face value, the arrangement cost nobody a visible decision. The prudential reforms that followed the Narasimham Committee’s report of 1991, requiring banks to recognise income and make provision against deteriorating assets by rule rather than by discretion, changed the arithmetic of tolerance: frozen loans to sick companies became measurable holes in bank balance sheets, recapitalisation of public banks became a recurring charge on the Union Budget, and a legal regime whose function was to postpone recognition of industrial losses collided head-on with a regulatory regime whose function was to compel it. The sickness Act’s last two decades were lived inside that collision, and the repeal, when the machinery finally allowed it, closed a question that fiscal policy had already answered.

The world the rescue statute was built for

The Act cannot be understood apart from the industrial economy that produced it. Indian industrial sickness had become a visible national problem through the 1970s and into the 1980s: textile mills in Bombay, Kanpur and Ahmedabad running below capacity or closed outright, jute mills along the Hooghly in decline, engineering and steel units carrying debts they could not service. The causes were mixed and often genuinely external. The licensing system had fixed capacities and technologies at the moment of approval, the term-lending institutions had financed long-gestation projects on thin equity, administered prices and import controls distorted whole sectors, and demand shocks fell on firms with no reserves. A company could be commercially doomed by decisions its managers had not taken, and a purely creditor-driven law of exit would have liquidated viable plant along with unviable management.

Exit, in any event, was barely available as a legal act. Winding up a company under the Companies Act 1956 meant proceedings before a High Court, and company courts carried heavy dockets in which liquidation stretched across years and sometimes decades, with assets decaying while the process ran. Closure of a larger industrial establishment under the industrial disputes law depended on government permission, which governments were reluctant to grant where employment was at stake, so the formal route to shutting a failed unit was obstructed at both ends. Nor did Indian law possess any general mechanism for the supervised restructuring of a company’s debts: no way to bind a dissenting minority of creditors to a negotiated plan, no professional cadre of administrators, no statutory framework within which a firm could trade under protection while its capital structure was rebuilt. Financial distress had exactly two legal destinations, a High Court liquidation of indefinite length or informal forbearance by the public sector banks and institutions that held most industrial debt, and informal forbearance tended to mean lending more money to postpone recognising the loss.

The Tiwari Committee, appointed in 1981 to examine the problem, recommended comprehensive legislation and a specialised quasi-judicial body to administer it. Parliament acted on that recommendation in 1985. The resulting Act, the Sick Industrial Companies (Special Provisions) Act, 1985, numbered Act 1 of 1986, announced its constitutional purpose openly: Section 2 declared that the Act was for giving effect to the principles in clauses (b) and (c) of Article 39 of the Constitution, the directive principles that ownership and control of the material resources of the community be distributed to subserve the common good and that the economic system not produce concentration of wealth to the common detriment. The premise was unmistakable. Industrial capacity was a community resource held on a kind of trust, a sick company was a public problem before it was a private default, and the state’s role was to diagnose the sickness in time and prescribe a cure, with liquidation as the admitted last resort rather than the organising idea.

That premise explains both the statute’s genuine ambitions and the shape of its machinery. Detection was to be timely: the Act created not only the category of the sick industrial company but also the category of the potentially sick company, whose board had to report early erosion of net worth and face its shareholders with the fact. Treatment was to be expert and centralised: a single national Board, staffed by persons of standing in finance, industry, law and administration, sitting in benches, with an appellate authority above it. The cure was to be a scheme, prepared by an operating agency drawn from the banking system, under which debts would be rescheduled, managements changed, units merged or sold, and sacrifices shared among creditors, shareholders and workers in proportions the Board approved. And while all of this proceeded, Section 22 held the ring, keeping the company’s assets and contracts intact against piecemeal enforcement. The failure that later consumed the regime was not a failure of intention. It was the failure of each of these choices under the pressure of the incentives they created.

The lenders’ republic: how industrial sickness was financed

The statute’s behaviour cannot be separated from the structure of the credit system it regulated. Large-scale Indian industry in the 1980s was financed overwhelmingly by public institutions. Long-term project debt came from the all-India term-lending institutions, the Industrial Development Bank of India, the Industrial Finance Corporation of India and the Industrial Credit and Investment Corporation of India, supplemented for smaller units by the state financial corporations; working capital came from the nationalised banks. Promoter equity in the companies they sponsored was characteristically thin, sometimes a small fraction of project cost, with the balance carried as institutional debt or as debentures the institutions themselves subscribed. This structure determined what industrial sickness meant in practice. When a large company failed, the loss did not fall on a dispersed market of bondholders or on private banks answerable to depositors in the ordinary commercial way. It fell, almost entirely, on institutions owned by the state, which were also the institutions charged with financing the next round of industrialisation. A sick company was therefore a fiscal event disguised as a corporate one, and every actor in the system understood that recognising failure meant the state recognising a loss to itself.

That identity of interests shaped the behaviour the statute encountered. A lending institution confronting a failing borrower faced a choice between enforcing its security, which crystallised the loss on its own balance sheet and invited questions about its original appraisal, or supporting a rehabilitation narrative, under which interest was rescheduled, concessions were granted, fresh working capital was advanced and the account remained, in the language of the time, standard rather than lost. The second course was nearly always the more comfortable, and the sickness Act institutionalised it. Once a company was before the Board, forbearance was no longer an individual banker’s indulgence but the official policy of a statutory scheme, and the operating agency appointed to design the rescue was ordinarily one of the very institutions whose exposure the rescue was meant to protect. The Goswami Committee’s complaint that rehabilitation rewarded inefficient and irresponsible entrepreneurs has to be read against this background. The deeper reward was not to the entrepreneur alone. It was to every participant in the credit chain who preferred a postponed loss to an admitted one, and the promoter, whose equity was usually the smallest sum in the structure, was simply the participant best placed to convert that collective preference into personal protection. A reform that blamed promoters while leaving this financing structure untouched would have changed the cast without changing the play, which is one reason the eventual successor statute reached beyond the sickness forum and reorganised the incentives of creditors themselves, through collective voting, professional management displacement and the credible threat of liquidation on a deadline.

How the machinery worked, section by section

The Act received the assent-era date of 8 January 1986 but commenced in two stages the following year: the institutional provisions took effect on 12 January 1987, and the operative chapters, Sections 15 to 34, followed on 15 May 1987, which is when the Board for Industrial and Financial Reconstruction became functional in substance. Section 4 established the Board as a body corporate with a chairman and not less than two and not more than fourteen other members, drawn from persons who had been High Court judges or who possessed special knowledge and at least fifteen years of professional experience in science, technology, economics, banking, industry, law, accountancy or administration. Section 12 provided for the Board’s jurisdiction to be exercised by benches of not less than two members. Section 5 constituted the appellate tier, the Appellate Authority for Industrial and Financial Reconstruction, whose chairman was required to be or to have been a judge of the Supreme Court or a judge of a High Court of not less than five years’ standing, sitting with not more than three members. Appeals from the Board’s orders lay to the Appellate Authority under Section 25, within forty-five days. Two features of this architecture deserve emphasis. The first is specialisation: for the first time, industrial sickness had a dedicated national forum outside both the ordinary courts and the departmental government. The second is finality: Section 26 barred the jurisdiction of civil courts over matters the Board or the Appellate Authority was empowered to determine and prohibited injunctions against their proceedings, while Section 32 gave the Act and schemes under it overriding effect over other laws, with only the foreign exchange regulation statute and the urban land ceiling statute excepted. The sickness forum was designed to be a complete legal world of its own.

Entry into that world was compulsory and self-executing in form. Section 15(1) imposed a duty, not an option, on the board of directors of a company that had become sick: within sixty days from the finalisation of the duly audited accounts of the financial year at whose end the sickness existed, or earlier if the directors had sufficient reasons to form the same opinion sooner, the board was required to make a reference to the Board. The theory was that those closest to the accounts would be compelled to disclose distress at the statutory moment. Section 15(2) added public triggers: the Central Government, the Reserve Bank, a state government, a public financial institution, a state level institution or a scheduled bank could each make a reference if it had sufficient reason to believe the company had become sick. In practice the self-reference dominated, and its timing was in the hands of the very directors whose company gained protection from the reference, a structural flaw examined in the discussion of Section 22 below.

On receipt of a reference, the Board’s task under Section 16 was inquiry. The Explanation to Section 16 fixed the inquiry as commencing on the date of receipt of the reference itself, a small provision with enormous consequences for the stay. The Board was to endeavour to complete the inquiry within sixty days. It could require information, appoint one or more persons to investigate and report, and, under Section 16(4), appoint special directors on the company’s board to safeguard the interests of the company, its shareholders and the public interest, directors whose appointment no resolution could annul and whose removal lay only with the Board. Section 17 then forced the fork on which the whole regime turned. The Board had to decide whether it was practicable for the company, on its own, to make its net worth exceed its accumulated losses within a reasonable time. If it was, the Board could simply give the company time. If it was not, and the Board considered preventive, ameliorative, remedial or other measures necessary in the public interest, the Board would direct an operating agency, meaning in practice a designated bank or financial institution, to prepare a scheme within such period, ordinarily not exceeding ninety days, as the Board specified.

The scheme under Section 18 was the regime’s therapeutic instrument, and its menu of measures was wide: the financial reconstruction of the company, the proper management of its affairs including a change in or takeover of its management, amalgamation with another company, sale or lease of part or whole of an undertaking, rationalisation of managerial, supervisory and general staff including retrenchment, and such other preventive or remedial measures as the company needed. A draft scheme was circulated for suggestions and objections within sixty days, the Board could modify it, and a sanctioned scheme came into force on the date the Board specified. Section 18(8) gave the sanctioned scheme its binding reach: it bound the sick company and any transferee company, and the shareholders, creditors, guarantors and employees of those companies. Section 19 addressed the scheme’s financial lifeblood, the reliefs and sacrifices required from banks, institutions, governments and others: their consent had to be sought within sixty days of circulation, extendable once by up to sixty more, and silence within the period counted as consent. The design deliberately denied any individual creditor a veto over a rescue the Board had approved, substituting a supervised collective process for unanimous bargaining, on the theory that a company cannot be reassembled while each creditor retains the power to dismantle it. Where consent was refused, the Board’s answer under Section 19(4) was to adopt other measures, including winding up. Section 19A allowed interim arrangements for continuing a company’s operations while an inquiry was still incomplete, so that production need not stop during diagnosis.

If the therapeutic path failed, the statute provided an exit of unusual finality. Under Section 20, where the Board, after inquiry and after giving the parties an opportunity of being heard, concluded that a sick company was not likely to make its net worth exceed its accumulated losses within a reasonable time while meeting its financial obligations, and that winding up was just and equitable and necessary in the public interest, it recorded and forwarded its opinion to the concerned High Court. The High Court was then obliged, on the basis of that opinion, to order the winding up of the company and proceed as under the Companies Act, and the Board could itself cause the company’s assets to be sold in the manner it directed and forward the proceeds to the High Court for distribution to those entitled. The consequence deserves plain statement: the pace of exit from a failed company was set entirely by the institution whose statutory mission was to prevent exit, and creditors who believed a company hopeless could test that belief in no other forum. The Board thus stood at both ends of corporate life and death: it was the physician of first resort and, short of the High Court’s formal order, the effective coroner. Notably absent from the design was any corresponding power over the process’s duration. Apart from soft endeavour clauses in the inquiry provisions, the statute imposed no enforceable deadline on the Board’s own deliberations, no consequence for a scheme that failed during implementation beyond fresh proceedings, and no sunset on the protection that inquiry triggered. Running through the design was an asymmetry that the later sections of this article keep meeting: the protections that benefited incumbent management operated automatically on the filing of a reference, while every corrective power over that management required a discretionary order, sought, heard and granted at the process’s own pace. The machinery was elaborate, expert and complete. It was also, in the hands of an unwilling patient, capable of running for a very long time.

One more feature of the exit route deserves record, because it qualifies the familiar claim that the Board alone delayed liquidation. Even where the Board moved with uncharacteristic speed to its Section 20 opinion, the winding up it triggered was a High Court process under the Companies Act, and company liquidation in India was itself one of the slowest proceedings in the legal system: petitions contested for years, official liquidators responsible for hundreds of estates with minimal staff, assets sold piecemeal long after their value as going concerns had evaporated. The sickness design therefore did not replace a working exit with a broken rescue. It interposed a rescue tribunal, with an indefinite timetable, in front of an exit process that was already broken in its own way, and the two delays compounded: a company could spend a decade before the Board being considered for revival and a further decade in liquidation being dissolved. When the Eradi Committee proposed telescoping revival into the Companies Act under a single tribunal, and when the Code later created a process in which liquidation is administered within the same timed framework as resolution, both reforms were responding to this compound failure. The problem was never only that rescue was slow. It was that Indian company law offered no fast version of either mercy or execution, and the sickness Act, designed as the mercy, inherited the tempo of the system around it.

When did the Section 22 stay actually begin?

The stay began on registration of the reference, not on any finding that the company was sick. In Real Value Appliances Ltd v. Canara Bank, decided on 5 May 1998, the Supreme Court held that once a reference was registered and information called for, an inquiry under Section 16 was deemed commenced and Section 22 applied immediately.

Could the Board change a sick company’s management?

It could, in two ways. Under Section 16(4), during the inquiry, the Board could appoint special directors on the company’s board to safeguard the interests of the company, its shareholders and the public, holding office on the Board’s terms. Under Section 18, a sanctioned scheme could itself provide for a change in, or takeover of, the company’s management.

A definition that arrived too late

Every part of the machine depended on the definition that switched it on, and the definition was where the deepest flaw lay. Section 3(1)(o) defined a sick industrial company as an industrial company, registered for not less than five years, which had at the end of any financial year accumulated losses equal to or exceeding its entire net worth. Net worth, under Section 3(1)(ga), was the sum of paid-up capital and free reserves, so the trigger can be stated arithmetically: a company entered the regime at the moment its losses had consumed every rupee of its shareholders’ funds. The qualifying conditions around the definition narrowed the field further. The company had to be an industrial company, one owning an industrial undertaking in a scheduled industry listed in the First Schedule to the Industries (Development and Regulation) Act 1951, and the notion of an industrial undertaking excluded ancillary and small scale units, so the smallest enterprises stood outside the statute altogether. The regime was a large-company law for organised industry, administered from Delhi, and its thresholds guaranteed that the patients who reached it were, almost by definition, in an advanced state of decay.

Consider what the trigger demanded as a matter of timing. A company’s net worth is a stock measured at the date its audited accounts are finalised, which is months after the financial year ends, and erosion to exactly one hundred per cent requires several successive years of heavy losses. Between the onset of real distress, which any cash-flow examination would reveal in the first bad year, and the statutory moment of sickness, a company could pass through years of unpaid interest, deferred wages, eroding plant and departing customers while remaining, in law, perfectly healthy. The Goswami Committee made this its central technical criticism in 1993, urging a definition of sickness keyed to default and early erosion rather than to total destruction of net worth. The Tiwari Committee’s preparatory work had contemplated identifying sickness at the erosion of fifty per cent of net worth, attended by cash losses, which would have brought companies within reach of intervention while half their shareholders’ funds survived; the enacted statute required one hundred per cent. Parliament in 1985 chose certainty over earliness, preferring a bright accounting line that no one could dispute to a judgement-based trigger that might be contested, and the price of that certainty was that the rescue agency met companies at the point where rescue was least likely to succeed. The statute even acknowledged the timing problem in its own structure, creating in Chapter IV the category of the potentially sick company, whose accumulated losses had eroded fifty per cent or more of its peak net worth over the preceding four financial years and whose board had to report the fact to the Board and place it before a general meeting of shareholders within sixty days, on pain of imprisonment for defaulting directors of between six months and two years. But the potentially sick provisions carried no stay, no inquiry and no scheme: they were an alarm bell attached to no engine, and directors had every reason to ring it as softly as the accounts allowed.

The definition also carried a distributional oddity that time exposed. When enacted, the Act excluded government companies from its reach, on the logic that the state’s own enterprises would be restructured by the state itself; in 1991, an amendment removed the exclusion and brought government companies within the definition, as public sector units accumulated losses on a scale that made their exemption from the discipline untenable. The episode is revealing about the regime’s politics. Each expansion of the net acknowledged that some category of large employer could not be left to ordinary enforcement, and each expansion enlarged the population entitled to the Section 22 stay. By the middle of the 1990s the statute covered much of large-scale Indian industry, public and private, at precisely the moment when the post-1991 economy was asking a different question: not how to nurse incumbents back to health under official supervision, but how to let capital and labour move from failed uses to productive ones. The definition that arrived too late was joined, over time, by a coverage that reached too wide, and both defects pointed the same way. The Act intervened at the end of a company’s life, in the largest possible set of cases, with a process that had no end of its own.

Parliament did revisit the definition once, and the terms of the revisit show how completely the late-intervention philosophy held. The Sick Industrial Companies (Special Provisions) Amendment Act of 1993 reduced the qualifying registration period in Section 3(1)(o) from seven years to five, marginally widening the class of companies old enough to be sick in law, but it left the substance of the test untouched: complete erosion of net worth, proved from audited accounts, remained the threshold of the legal condition. The amendment came in the same year as the Goswami report, whose central recommendation was that the threshold itself be rebuilt around default and early erosion, and the juxtaposition is the point. Presented with a critique of where the line was drawn, Parliament moved a different line, the age of the company, and left the erosion requirement standing. Amendment within the philosophy was politically available; amendment of the philosophy was not, because a default-based trigger would have transferred the initiative in the system from the debtor’s audited accounts to the creditor’s unpaid bill, which is to say from the party being protected to the parties bearing the loss. That transfer had to wait for a different statute altogether, and another twenty-three years.

Did a sanctioned scheme bind creditors who had never consented to it?

Yes. Section 18(8) made a scheme binding on the sick company and any transferee company, and on their shareholders, creditors, guarantors and employees. Under Section 19, a creditor required to give assistance had sixty days to consent, extendable by sixty more, and silence within the period counted as consent, so a scheme could bind a creditor who never agreed.

Could a sick company be wound up while its case was before the Board?

Only through the Board itself. Section 22 barred proceedings for winding up a company under inquiry, under a scheme in preparation or implementation, or with an appeal pending, except with the consent of the Board or the Appellate Authority. The road to liquidation ran through Section 20: the Board’s opinion, forwarded to the High Court, which ordered the winding up.

The consent jurisdiction: how the stay worked in practice

Between the statute’s text and the creditor’s experience of it stood a piece of machinery that the cases mention constantly and commentary rarely pauses on: the consent jurisdiction. Every bar in Section 22(1) was subject to the previous consent of the Board or, where an appeal was pending, of the Appellate Authority, and that single phrase converted an absolute stay into a discretionary gate. A bank that wished to enforce its security, a tax authority that wished to attach property, a landlord or decree-holder who wished to execute, each had to apply to the Board and persuade it that the proposed action should be allowed notwithstanding the inquiry or the scheme. The Board, in deciding, weighed the very question its rescue mission disposed it to answer in the company’s favour: whether the enforcement would prejudice the revival under examination. Consent was therefore not a rubber stamp occasionally withheld; it was a second litigation, conducted before the institution whose statutory sympathies lay with continuation, and it consumed the same calendar as the inquiry it accompanied. For creditors the practical law of Section 22 was thus not merely that they could not proceed. It was that the permission to proceed had to be begged from the debtor’s protector.

The courts supervised this gate at its edges. They held that the Board’s consent jurisdiction did not swallow every species of proceeding that touched a sick company: criminal prosecution for the dishonour of cheques under the Negotiable Instruments Act was held by the Supreme Court in Kusum Ingots and Alloys Ltd v. Pennar Peterson Securities Ltd in 2000 not to be a proceeding for the recovery of money within the bar, so the criminal process ran its course while the civil remedies slept. The boundary-drawing is instructive about the shelter’s true legal shape. Section 22 froze the enforcement of obligations; it did not immunise the company or its officers from the criminal law, from proceedings that sought no execution against assets, or from the consequences of liabilities, like a guarantor’s, that the section did not name. What it froze, it froze completely, and what it froze was exactly the set of remedies through which credit disciplines a borrower. A creditor whose loan was sound in documents and hopeless in practice had, during the years of an inquiry, three lawful occupations: wait for the Board, apply to the Board, or write the debt down in its own books and carry on. The third occupation, multiplied across the banking system, is the fiscal story told in this article’s opening sections, and it explains why the constituency for repeal, when repeal finally became possible, was led by the lenders the regime had been designed to overrule.

Section 22: a rescue stay that became a shelter

Section 22(1) deserves to be read closely, because the controversies of thirty years are all latent in its drafting. Where an inquiry under Section 16 was pending, or a scheme referred to in Section 17 was under preparation or consideration, or a sanctioned scheme was under implementation, or an appeal under Section 25 was pending, the section barred four families of action in relation to the sick company: proceedings for its winding up; proceedings for execution, distress or the like against any of its properties; the appointment of a receiver in respect of those properties; and the institution or continuation of any suit or other legal proceeding for the recovery of money, or for the enforcement of any security against the company, or of any guarantee in respect of a loan or advance granted to it. Every one of these bars yielded to a single key: the previous consent of the Board or, where an appeal was pending, of the Appellate Authority. Section 22(3) let the Board go further and declare, in relation to a company under inquiry or with a scheme under preparation, that specified contracts, assurances of property, agreements, settlements, awards, standing orders or other instruments would remain suspended or operate with adaptations for a declared period that could not exceed two years at a time, renewable year by year up to a total of seven years. Section 22(5) stopped the clock of limitation for the duration of a suspension, and Section 22A empowered the Board to direct the company not to dispose of or otherwise deal with its assets during the inquiry, the preparation of a scheme, or the interval after a winding-up opinion had been recorded. Read together, these provisions did not merely pause enforcement. They reallocated control over the company’s legal environment to the Board, for periods measured in years, while leaving possession and management of the company itself exactly where the failure had occurred.

The courts, interpreting the section, made its breadth plainer still. In Gram Panchayat v. Shree Vallabh Glass Works Ltd in 1990, the Supreme Court held that the bar reached a gram panchayat’s attempt to recover property tax dues by attachment: even a local body’s statutory recovery against a sick company required the Board’s consent. In Maharashtra Tubes Ltd v. State Industrial and Investment Corporation of Maharashtra in 1993, the Court held that a state financial corporation could not proceed under its own statute to take over or sell the unit of a company under inquiry, since such action was execution or distress by another name. In Deputy Commercial Tax Officer v. Corromandal Pharmaceuticals in 1997, the bar was applied to the recovery of sales tax dues for the period of the scheme. The Real Value Appliances decision of 1998 fixed the stay’s starting point at the registration of the reference, setting aside orders for a receiver and a provisional liquidator that the Bombay High Court had passed after registration, even though the company had kept the High Court in ignorance of the reference: if assets could be seized before the Board decided, restoration of the position afterward would often be impossible. In Rishabh Agro Industries Ltd v. P.N.B. Capital Services Ltd, the Court carried the bar a step further still, holding that it operated even where a winding-up order had already been passed, so that not even a completed judicial step toward liquidation displaced the Board’s process. And in Shree Chamundi Mopeds Ltd v. Church of South India Trust Association in 1992, the Court marked a genuine limit: eviction proceedings by a landlord against a sick tenant company, which sought possession of premises rather than execution against assets or recovery of money, fell outside the categories the section names. The pattern across the case law is of a bar construed at its full width, extending to tax authorities, financial corporations, landlords suing for money and decree-holders alike, while stopping at proceedings that neither executed against property nor recovered a debt.

Two later decisions define the shelter’s outer defences. In Kailash Nath Agarwal v. Pradeshiya Industrial and Investment Corporation of U.P. Ltd in 2003, the Supreme Court held that proceedings against a guarantor of the sick company’s loans were not barred: Section 22 protects the company’s assets and the revival process, and a guarantor’s independent liability could be enforced notwithstanding the stay, a ruling that gave lenders one surviving route to a part of their security while confirming that the principal debtor remained untouchable. In Jay Engineering Works Ltd v. Industry Facilitation Council in 2006, the Court addressed the contest between the sickness Act’s overriding clause and a later statute protecting small suppliers’ interest on delayed payments, holding that the arbitration mechanism of the later Act could not proceed against a sick company in the teeth of Section 22 and Section 32: the sickness statute, with its express overriding effect, displaced the competing remedy. Each judgment was, on its own terms, a faithful construction of the text Parliament enacted. Their cumulative effect was to demonstrate that the shelter was not an accident of administration or a loophole discovered by ingenious lawyers. It was the statute working as written, and it could be ended only by writing a different statute.

The defence of Section 22, made at the time and repeated by those who administered the regime, was that the critics mistook a moratorium for a gift. No restructuring in any jurisdiction proceeds without a stay; the United States’ Chapter 11, which Indian reformers admired, imposes an automatic stay at least as sweeping, and no one calls the American stay a shelter for defaulters. The difference, the defence continued, lay not in the stay but in what surrounded it. Chapter 11 pairs its stay with disclosure duties, creditor committees, the real possibility of management displacement and a court that confirms or rejects a plan within a disciplined calendar. SICA paired its stay with a definition that admitted companies years too late, a tribunal without enforceable deadlines, operating agencies drawn from the same lending institutions asked to take losses, and promoters who retained possession throughout. On this account Section 22 was a sound component in a machine whose other components failed, and the true defendant in the repeal debate was the process, not the pause. The verdict this article reaches, weighing both sides, is that the distinction is thinner than the defence supposes. A stay is only ever as benign as the process it serves, and a legislature enacting Section 22 in a statute with no terminal discipline for the process was enacting the shelter, whatever it intended. Parliament’s own eventual judgement, delivered through the design of the Insolvency and Bankruptcy Code, accepted that logic: the Code kept a moratorium, in Section 14, but re-engineered everything around it, transferring management to an insolvency professional on admission and putting the admission decision on default rather than on the exhaustion of net worth.

The stay’s third constituency: workers inside the sickness process

No account of the shelter is complete without the constituency in whose name it was most often defended. A sanctioned scheme bound not only creditors and shareholders but, under Section 18(8), the employees of the sick company, and the scheme menu in Section 18 expressly contemplated the rationalisation of managerial, supervisory and general staff, including retrenchment of employees in accordance with law. Workers therefore stood inside the process in a double capacity. They were beneficiaries of its central promise, since every month of continued operation under the stay was a month of wages that liquidation would have ended, and their unions were heard in scheme proceedings as parties whose consent to a rescue plan could determine whether the plan functioned at all. They were also among its designated sacrificers, since schemes routinely spread their costs across every constituency the Board could bind: creditors took rescheduling and write-downs, shareholders took dilution, governments took deferral of dues, and workers took wage restraint, deferred arrears and, in the harder schemes, reductions in the workforce itself.

This double position explains a political fact that purely creditor-focused accounts of the regime miss. The sickness process had an organised constituency for its own continuation that no liquidation system possesses. A company’s creditors, dispersed among institutions, gain from speed; its workers, concentrated in one place and one union, gain from continuation and can say so in a single voice, to the tribunal, to the state government and to the press. When critics described the Board as a shelter for defaulters, defenders could answer with the payroll: behind every contested stay stood a workforce for whom the stay was not a promoter’s stratagem but the difference between employment and the street, in towns that frequently offered no second employer. The answer was genuinely strong for genuinely marginal companies, firms whose sickness came from a sectoral shock or a financing failure rather than from diversion or incompetence, and it is the reason the regime’s abolition could not be a simple act of creditor emancipation. The Code that replaced it had to make its own settlement with employment, and did so in its characteristic way, not by promising continuation, which it does not, but by making resolution, the sale of the enterprise as a going concern where a buyer exists, preferable in practice to liquidation and its dispersal of the workforce. The political problem the Board embodied did not end in December 2016. It was re-answered, on harder terms.

The record of the Board, and the charge of shelter examined

Numbers first, attributed where they belong. The most authoritative single account remains the Eradi Committee’s, compiled from the Board’s record for the period 1987 to 2000 and quoted in later Supreme Court judgments: 3,068 references in thirteen years, of which 264 ended in revival, 741 in recommendations for winding up, 626 in dismissal as not maintainable, and 375 in negotiation toward revival, with 1,062 cases still undecided at the period’s end. Compilations from the Board’s own case statistics for the following years show the pattern hardening rather than easing: by the end of 2007, registered references had reached 5,471, revival schemes sanctioned stood at 825, and recommendations for winding up at 1,337. Anyone who wishes to test these figures against the primary material will find the Board’s record scattered across decades of printed orders, Gazette notifications and returns in mixed formats, and working through it is considerably eased by opening the documents through an online PowerPoint viewer for presentation decks and slide records that renders them without desktop software. However the figures are approached, their shape is consistent across every compilation: winding up recommendations comfortably exceeded sanctioned revivals, dismissals for non-maintainability formed a large share of disposals, and the residue of pending cases grew faster than the tribunal could clear it.

The charge that the regime sheltered defaulters rests on more than outcomes; it rests on findings about conduct, and those findings must be attributed rather than asserted. The Goswami Committee recorded in 1993 that relief under the rehabilitation framework indirectly worked to reward inefficient and irresponsible entrepreneurs, since the promoter who had presided over failure retained the enterprise while institutions and governments absorbed the sacrifices. The Eradi Committee, seven years later, found the Board’s effectiveness severely undermined by enormous delays, a finding directed at the institution rather than at individual promoters but one that completes the mechanism: delay was not a neutral misfortune in this regime, because every year of delay was a year of Section 22 protection enjoyed by the incumbent management at the creditors’ expense. Section 24 of the Act itself acknowledged the misconduct risk, empowering the Board, where it was satisfied that a person had been guilty of misfeasance or had diverted the company’s funds or managed its affairs in a manner highly detrimental to the company’s or the public interest, to direct that no financial institution provide that person financial assistance for ten years. A statute does not arm its tribunal against fund diversion by the managements before it unless diversion is a known pattern of the jurisdiction it governs. The prosecutions and directions under such provisions were rare relative to the scale of the caseload, which is itself part of the record: the corrective powers existed on paper, required satisfaction after hearing, and moved at the same deliberate pace as everything else in the building.

The counter-reading, which the evidence also supports, is that the Board’s apparent failures were partly the failures of its mandate. A very large share of the companies referred to it were, by the statutory definition, already stripped of net worth: the tribunal was handed terminal patients and then graded on its cure rate. Some sanctioned schemes did succeed, and 264 revivals in the Eradi period, together with 375 more under negotiation, are not nothing in an economy where the alternative forum was a High Court liquidation of indefinite duration. The Board also performed work that disappears from the statistics entirely: it was the forum in which banks, governments, workers and managements were compelled to sit in one room and confront a company’s position on a single record, and in an economy without any other restructuring forum, that clearing-house function had real value even where the eventual answer was winding up. Nor should the political constraint be discounted, as the opening sections of this article argued: a tribunal ordered to prefer revival, sitting in a country where the closure of a major employer could dominate a state’s politics, will predictably produce delay, and the delay then belongs as much to the preferences of the democracy as to the competence of the institution. The fair conclusion is two-level. As an account of incentives, the shelter charge is correct: the regime systematically transferred the cost of industrial failure from promoters to creditors and the public, and rational promoters used it as designed. As an account of blame, the shelter metaphor misleads if it suggests that a differently staffed Board, under the same statute, would have produced a different history. The statute made the shelter; the Board merely kept its roof repaired.

Reading the Board’s numbers: what the categories mean

The figures quoted in debates about the regime are often used loosely, and the categories deserve a careful reading, because each measures a different thing. A reference dismissed as not maintainable, 626 of them in the Eradi Committee’s count, was a reference that failed the statute’s own screens: the company was not an industrial company within the scheduled-industry definition, or it had not been registered for the qualifying period, or its audited accounts did not yet show accumulated losses equal to its entire net worth. A substantial share of the Board’s docket, in other words, consisted of companies that were distressed enough to be brought to the tribunal but not sick enough, in the statute’s demanding sense, to be treated there, which is the clearest statistical trace of the definition’s defect: the door was narrow, and a crowd pressed against it. Companies under negotiation for revival, 375 in the same count, were cases in which a scheme was being formulated or discussed, a category that says something about process and nothing about outcome; negotiation could end in sanction, in abandonment, or in a winding-up opinion years later. A sanctioned scheme, 825 by the end of 2007 in the Board’s case statistics, was a decision, not a result. Section 18(12) charged the Board with monitoring the implementation of the schemes it sanctioned, and the monitoring jurisdiction existed precisely because sanctioned schemes failed in implementation with some regularity, returning companies to the Board for modification of the scheme, fresh inquiry, or the winding-up opinion that had been deferred. A revival, the 264 of the Eradi count, was the narrowest category of all: a company that had passed through the process and emerged with its net worth restored.

Two conclusions follow for anyone citing the record. The first is that the familiar rhetorical contrast, between the handful of revivals and the mass of winding-up recommendations, is fair as far as it goes but understates the regime’s failure in one respect and overstates it in another. It understates it because the pending stock, 1,062 undecided cases at the end of the Eradi period and growing thereafter, contained the regime’s true characteristic product, which was neither revival nor burial but suspension: companies kept in a legal condition in which they could not be rescued, could not be closed, and could not be sued. It overstates the failure if it treats every winding-up recommendation as a defeat, since for a company whose net worth had been entirely consumed before the reference was even filed, an orderly recommendation for winding up, with the Board able to direct the sale of assets under Section 20, was often a better public outcome than another decade of pretended convalescence. The second conclusion concerns grading. A tribunal whose statute admits only patients with completely eroded net worth is being sent the cases least capable of cure, and its revival rate is partly a measurement of the admission rule rather than of the tribunal’s skill. That is why the reform debate, from Goswami onward, kept returning from the Board’s performance to the definition that governed admission. The numbers were an argument about design before they were an argument about competence, and the committees that read them most carefully treated them that way.

The reform committees, and what each one actually recommended

The Goswami Committee, formally the Committee on Industrial Sickness and Corporate Restructuring, was constituted in April 1993 under the chairmanship of Dr Omkar Goswami and submitted its report to the Ministry of Finance on 13 July 1993. Its recommendations reached to the root of the design. Sickness should be redefined around default and early erosion rather than the complete destruction of net worth, so that intervention could begin while intervention could still help. The Board’s role should be modified from that of a sanctioning authority for open-ended rehabilitation packages toward that of a facilitator of negotiated restructuring between companies and their creditors. Rehabilitation assistance, the Committee objected, indirectly rewarded inefficient and irresponsible entrepreneurs, because the costs of failure were socialised while control remained privatised. And winding up, where winding up was the honest answer, should be fast: the Committee recommended fast-track winding-up tribunals in the five metropolitan cities of Mumbai, Kolkata, Chennai, Delhi and Bangalore, so that exit could compete with rescue as a practical outcome instead of existing only as a threat that no participant believed. The report was received, debated and substantially not implemented. The sickness Act was amended in the 1990s, including the reduction of the qualifying registration period in the definition of a sick company from seven years to five in 1993, but the definition’s net-worth core, the Board’s structure and Section 22 all survived the decade intact.

The Eradi Committee, constituted in 1999 under Justice V. Balakrishna Eradi as the Committee to examine the law relating to insolvency and the winding up of companies, reported on 31 July 2000 and went the distance Goswami had not. It recommended that the sickness Act be repealed altogether and that the subject of revival and rehabilitation be telescoped into the Companies Act 1956, administered through a new National Company Law Tribunal that would combine the jurisdictions then scattered among the Board, the Company Law Board and the High Courts’ company jurisdiction. The intellectual move is worth pausing on. Eradi did not propose to abolish the rescue function; the Committee accepted that companies in distress needed a forum for supervised revival. It proposed to abolish the separate rescue universe, the self-contained statutory world in which a company entered sickness law and left company law behind, and to rehouse the function inside the general statute governing companies, under a generalist tribunal with company-wide jurisdiction. The later Bankruptcy Law Reforms Committee, chaired by T. K. Viswanathan and reporting in November 2015, completed the intellectual journey from the other direction: beginning from the economics of credit, it proposed a single insolvency code for companies and individuals alike, in which the trigger was default, the decision-maker on admission was a tribunal, control passed to an insolvency professional, and the creditors in committee chose between resolution and liquidation within a fixed period. Between Eradi in 2000 and Viswanathan in 2015, the question was never whether the sickness regime should end. Every committee that examined it said that it should. The questions that consumed fifteen years were institutional: what replaces the Board, who staffs the replacement, and can the replacement survive constitutional challenge.

Three attempts to build the successor

The first attempt followed Eradi directly. The Companies (Second Amendment) Act 2002 wrote a complete sick-companies code into the Companies Act 1956 as Sections 424A to 424L, abolished the Company Law Board and the sickness Board and its appellate authority in prospect, and created the National Company Law Tribunal to inherit their work; the full story of that amendment and of the 1956 Act’s long replacement is told in this series’ account of the replacement of the Companies Act 1956. Almost none of the 2002 design was ever brought into force. The obstacle was litigation about the tribunal itself. In R. Gandhi v. Union of India, Writ Petition No. 2198 of 2003, the Madras High Court held on 30 March 2004 that the tribunal as designed in the 2002 amendment could not stand, on grounds concerning its composition and its displacement of the High Courts’ jurisdiction, and the consequence recorded in that litigation was precise: the government could not notify the provisions abolishing the sickness Board. The Supreme Court, in Union of India v. R. Gandhi in 2010, upheld the creation of the tribunal in principle while requiring corrections to its design, but by then the legislative vehicle had changed. The Companies Bill that became the Companies Act 2013 carried the tribunal into the new statute, and no government chose to spend the intervening years commencing a tribunal code inside an Act that was itself about to be replaced. The 2002 code for sick companies joined the lengthening list of enacted Indian provisions that existed in the Gazette and nowhere else.

The second attempt was Chapter XIX of the Companies Act 2013, Sections 253 to 269, a self-contained code for the revival and rehabilitation of sick companies under the National Company Law Tribunal that the 2013 Act created. It modernised the surface of the design, determining sickness by reference to defaults in repayment rather than waiting solely for balance-sheet exhaustion, yet it never operated for a single day. The chapter was never notified into force, and the Insolvency and Bankruptcy Code then amended the 2013 Act to omit it entirely, a chapter of a major statute deleted before commencement, leaving no decided case, no scheme and no tribunal order under it anywhere in the reports. Chapter XIX matters to this article because it proves that the sickness regime’s survival into the middle of the following decade was not caused by any lack of drafted alternatives. By 2013 there were two complete replacement codes on the statute book or in enacted text, the 2002 insertions and the 2013 chapter, and the old Board outlived both, because neither replacement possessed the one thing the transition required: a constituted, functioning tribunal able to receive the Board’s jurisdiction, since the National Company Law Tribunal itself was constituted only on 1 June 2016, under the 2013 Act, after the constitutional design questions had been settled and fresh appointments made.

Between the second attempt and the third stands the drafting exercise that changed the terms of the whole subject. The Bankruptcy Law Reforms Committee, appointed in 2014 under T. K. Viswanathan, did not begin by asking how the sickness regime might be repaired. It began from the condition of the credit system, in which a creditor of a defaulting Indian company faced a scatter of partial remedies, debt recovery tribunals, securitisation enforcement, company court winding up and the sickness process, no one of which delivered a timely collective outcome, and it concluded that the landscape should be replaced by a single code rather than amended at the edges. The Committee published its report and a draft code in November 2015, and the government’s legislative choice that followed is the political fact at the centre of the repeal’s timing. A government determined to end the sickness regime by the shortest route could have constituted the tribunal under the Companies Act 2013, commenced Chapter XIX, and notified the Repeal Act, all with instruments already enacted. The route actually taken was longer and larger: wait for the comprehensive code, constitute the tribunal in June 2016 for the code’s purposes, and let the repeal ride on the code’s commencement. The sickness regime survived its second replacement, in other words, because the state preferred to bury it inside a general settlement of insolvency law rather than to execute the narrower sentence that had been waiting since 2004. Whether that preference was wisdom or indulgence depends on the value placed on the code’s coherence; what is not contestable is that it was a preference, exercised in full knowledge that each year of it extended the Section 22 shelter for the companies then inside the old process.

The third attempt succeeded. The Insolvency and Bankruptcy Code of 2016, which received the President’s assent on 28 May 2016, approached the sickness problem by dissolving it into a general law of default, and the Insolvency and Bankruptcy Code 2016 as the successor regime is examined in full elsewhere in this series. Its design choices read as a point-by-point answer to the record assembled in this article. Where the sickness Act waited for net worth to vanish, the Code is triggered by a default in payment. Where the sickness Act was set in motion, in the ordinary case, by the debtor’s own board, the Code lets financial creditors, operational creditors and the corporate debtor itself apply. Where a reference under the old law left management in possession behind a stay, admission under the Code vests the management of the corporate debtor in an insolvency resolution professional and suspends the powers of its board. Where the old process had no terminal date, the Code as enacted required the resolution process to be completed within one hundred and eighty days, extendable once by up to ninety. And where Section 22 had protected the company against the world while the Board deliberated, the Code’s Section 14 moratorium protects the estate briefly and instrumentally, as an incident of a process whose control has already changed hands, with Section 238 giving the Code overriding effect over inconsistent laws. The replacement, in short, was not a renovated sickness Act. It was a different theory of what financial failure is: not a disease of the industrial body requiring state therapy, but a breakdown of payment requiring a collective decision by those whose money is at stake, taken quickly, with exit as a respectable answer. The institutional furniture differed as much as the theory. The sickness regime’s appeal lay to a specialist appellate authority whose world ended at the writ jurisdiction of the High Courts; the Code routes appeals from the tribunal to the National Company Law Appellate Tribunal and onward to the Supreme Court on questions of law. The sickness regime’s rescues were designed by operating agencies chosen from the lending institutions themselves; the Code’s processes are run by insolvency professionals, a licensed and regulated cadre overseen by a dedicated regulator, the Insolvency and Bankruptcy Board of India, which also registers the information utilities intended to make default a documented fact rather than a matter of allegation. Each substitution replaces an insider of the old credit system with an office of the new one, accountable to a regulator and removable for cause. The pattern completes the point about decision machinery: the sickness Act trusted the existing institutions of Indian industrial finance to correct themselves under a tribunal’s supervision, while the Code, written after three decades of that experiment, built new institutions because it did not.

A statute of the old economy

There is a further reason the repeal took the shape it did, and it lies in the date 1991 rather than in any committee report. The sickness Act was a characteristic product of the economic constitution that preceded the reforms of that year. Its very scope was defined by reference to the First Schedule of the Industries (Development and Regulation) Act 1951, the statute that organised industrial licensing, so the sickness regime’s jurisdiction was a map of the licensed economy. Its declaration in Section 2 tied it to Article 39 of the Constitution and to a vision of material resources held for the common good. Its cast of institutions, the development banks, the nationalised commercial banks, the state financial corporations, a board of officials and experts dispensing supervised rehabilitation, assumed a state that owned the lenders, licensed the borrowers, fixed many of the prices, and stood ready to referee the consequences of its own decisions. Within that constitution the Act was not an eccentricity. It was the logical completion of the system: an economy administered at entry, through licensing, would naturally be administered at the point of failure too.

The reforms of 1991 onward dismantled that constitution piece by piece, delicensing industry, opening sectors to private and foreign capital, admitting new private banks, and subjecting public sector lenders to prudential norms that made the concealment of bad loans progressively harder. The sickness Act was never re-founded on the new premises. It simply persisted, an administered-rescue machine of the control era operating inside an economy increasingly organised around contract, competition and enforcement, and the friction between the statute and its environment explains several of the pathologies usually blamed on the Board alone. New creditors, private banks and suppliers who had never belonged to the forbearance culture of the development finance institutions, experienced Section 22 not as industrial policy but as confiscation of their remedies by a tribunal they had not chosen. Parliament’s own later statutes began to vote against the regime: the Recovery of Debts legislation of 1993 created tribunals for bank recovery that the sickness stay then obstructed, and the Securitisation Act of 2002, a creditor-rights statute of the new economy, cut the three-fourths proviso into Section 15 and empowered a qualified majority of secured creditors to abate a reference altogether, as the Supreme Court confirmed in the Madras Petrochem case in January 2016. By the time the Repeal Act was passed in 2003, the question before Parliament was therefore not merely whether a tribunal had performed badly. It was whether the state’s role in corporate failure would remain that of a therapist standing above the market, or become that of a rule-setter providing a swift collective procedure and then enforcing its outcome. The Insolvency and Bankruptcy Code is the second answer, enacted in full. The thirteen-year interval between the two answers is the measure of how long an economic constitution can persist in a statute book after the economy it described has gone.

The thirteen-year repeal: anatomy of a notification gap

The Sick Industrial Companies (Special Provisions) Repeal Act bears the year 2003 in its title and is, in the official numbering, Act 1 of 2004: the President assented to it on 1 January 2004 and it was published in the Gazette of India on 2 January 2004. Its operative scheme was terse. The sickness Act would stand repealed on a date the Central Government appointed by notification, the Board and the Appellate Authority would stand dissolved, and the consequences for pending business were set out in Section 4, with savings in Section 5 that protected, among other things, schemes already sanctioned. Like many Indian statutes, it carried its own commencement clause, and like a smaller number of consequential ones, that clause became the whole story. No notification appointing the day was issued in 2004, or in any of the eleven years that followed. The repealing Act sat on the statute book as an enacted intention, while the Act it repealed continued in undiminished operation, and lawyers cited both, one as the law in force and the other as the law in waiting.

The clause that produced this result repays a close look, because it was as short as it was consequential. Section 1(2) of the Repeal Act provided that the Act would come into force on such date as the Central Government may, by notification in the Official Gazette, appoint. Parliament attached no long-stop date, no requirement that the government report its reasons for deferral, and no provision by which the appointment could be compelled. Compare the drafting choice available and not taken: a repeal expressed to commence on a fixed date, or on the commencement of a named successor provision, would have made the gap legally impossible and forced the tribunal question to be settled on a schedule. The appointed-day form was chosen, as it is chosen in a large share of Indian legislation, precisely because it transferred the timing risk to the executive, and the executive then held the risk for thirteen years. There is a lesson in drafting here that extends well past insolvency. A legislature that wishes an institution abolished should say when, or should name the event on which abolition depends and place a duty on someone to certify the event. A legislature that delegates the date without conditions has not abolished anything; it has announced an intention and adjourned.

The easy explanation is administrative neglect, and it is wrong in a way that matters. A repeal of the sickness regime was not a self-executing event; it was a handover. On the morning after commencement, references pending before the Board needed a forum, sanctioned schemes under implementation needed a supervisor, appeals needed an appellate home, and new sickness needed somewhere to go. The intended destination, in the scheme of 2002 and 2003, was the National Company Law Tribunal, and the tribunal did not exist. Its statutory design had been struck at by the Madras High Court in 2004, its constitutional footing was not settled until the Supreme Court’s decision of 2010, its statutory home shifted from the 1956 Act to the 2013 Act in the interval, and it was constituted in fact only on 1 June 2016. The repeal, throughout those years, could not commence because the institution it depended on had not been born: this is the pattern this article calls repeal by dependency, in which the commencement of a repealing Act is structurally conditional on machinery outside itself, and the delay measures the life of the dependency rather than the intentions of the government of the day. The point becomes clearer against the series’ contrasting case of a notification gap caused by design rather than dependency: the Whistle Blowers Protection Act, where commencement waited on an amending Bill and executive choice, not on any missing institution. A reader who lumps the two gaps together as the familiar Indian habit of enacting laws and forgetting them will misjudge both. One gap was a decision repeated annually; the other was a queue of prerequisites, each of which can be dated and tested against the record.

That is not to acquit the governments of those years. The dependency was genuine, but it was not treated as urgent. Between the Supreme Court’s tribunal decision in 2010 and the constitution of the National Company Law Tribunal on 1 June 2016 lie six years in which a constituted tribunal under the Companies Act 2013 could have received the sickness jurisdiction and unlocked the repeal, and the companies chapter of the 2013 Act was itself left unnotified throughout. The practitioner Alok Dhir, of Dhir and Dhir Associates, summarised the constraint from within the insolvency profession when the end finally came: if an Act is repealed, something else must be put in its place, and through those years the tribunal’s own constitutionality was under challenge. The summary is accurate as far as it goes, but dependency explains only the impossibility of commencing the repeal, not the slowness of removing the impossibility. The balanced verdict is that the thirteen-year gap had a structural cause and a political accelerant. The structure made 2004, 2005 and the years of live tribunal litigation impossible starting dates. The politics made the prerequisite, an appointments-and-design exercise fully within executive and legislative control after 2010, wait until a new insolvency statute in 2016 supplied the occasion. Understanding the National Company Law Tribunal and its appellate authority, and the long litigation over what kind of body it had to be, is therefore not a detour from the story of the repeal. It is the story’s explanation.

December 2016: the repeal, the abatement and the savings

The end, when it came, was engineered with a precision that acknowledged the strangeness of the whole position. The Insolvency and Bankruptcy Code, by its Section 252 and its Eighth Schedule, amended the Repeal Act itself, substituting a new Section 4(b) with effect from 1 November 2016, so that the transition rules which would govern the old Board’s pending business were the Code’s rules rather than the simpler scheme of 2003. On 25 November 2016 the Ministry of Finance issued the commencement notifications, S.O. 3568(E) and its companion, under which the Repeal Act would take effect on 1 December 2016 and the substituted Section 4(b) would operate with it; the Code’s provisions on corporate insolvency were brought into force for the same appointed day, so that the fate of the legacy cases inherited from the old regime would be decided inside the new system from its first morning. On 1 December 2016 the sickness Act stood repealed, the Board for Industrial and Financial Reconstruction and the Appellate Authority stood dissolved, and a statutory world that had opened in January 1987 closed twenty-nine years later, its last cases extinguished not by decision but by a rule.

The rule was abatement. Substituted Section 4(b) provided that any appeal preferred to the Appellate Authority, any reference made to the Board, and any inquiry or proceeding pending before either body immediately before the commencement of the Repeal Act would stand abated. Abatement is a hard-edged legal event: the proceeding does not transfer, is not decided, and leaves no order on the merits; it simply ceases to exist, and with it ceased every Section 22 stay that had depended on pendency, exposing companies that had lived behind the stay for years to their creditors in the ordinary law. The section softened the landing in two ways. A company in respect of which an appeal, reference, inquiry or proceeding had abated could make a reference to the National Company Law Tribunal under the Code within one hundred and eighty days from the commencement of the Code, translating its claim to supervised rescue into the only vocabulary the legal system still spoke. And a second proviso removed the fee for such a reference, so that no company would lose its route to the tribunal for want of a filing fee in the transition. Section 5 of the Repeal Act protected what abatement would otherwise have destroyed unfairly: schemes that the Board had already sanctioned were not annulled by the repeal, and their implementation and supervision passed into the successor framework, a distinction between proceedings still in argument and decisions already taken that the courts were soon asked to police.

Policing arrived through delegated legislation first and litigation immediately after. In 2017 the Central Government issued a Removal of Difficulty Order, S.O. 1683(E), under the Code’s Section 242, adjusting Section 4(b) to make the position of sanctioned schemes explicit: the implementation and supervision of a sanctioned scheme would lie with the National Company Law Tribunal under the Code, and appeals in such matters would lie to the National Company Law Appellate Tribunal within ninety days. The classification the transition finally embodied was therefore threefold. Proceedings in flight on 30 November 2016 abated, with a one hundred and eighty day window and no fee for a fresh start under the Code. Schemes already sanctioned survived, under new management as to supervision and appeals. And everything else about the sickness regime, the definition, the reference, the stay, the operating agency, ended without remainder. For the companies caught in the first class, including some whose draft schemes had been under preparation for years and were close to sanction, the distinction between the first and second classes was the difference between keeping a decade of negotiated progress and starting again before a different tribunal under a different theory of law.

The dissolution itself, as an institutional event, was correspondingly abrupt. The Repeal Act provided no successor secretariat, no transfer of the Board’s establishment to a continuing body, and no winding-down administration, because the combination of abatement for unfinished business and savings for finished business disposed of the institution’s entire legal estate in advance. On the appointed day the Board and the Appellate Authority simply ceased to exist as functioning bodies: their benches heard nothing further, their members’ tenure ended with the offices themselves, and such of their records as retained legal significance were those embodied in sanctioned schemes, which passed into the successor tribunal’s supervision under the settlement described in this section. Institutions of thirty years’ standing usually leave a residue of staff, premises and unfinished correspondence that a successor must absorb. The sickness Board left almost none, and the cleanliness of the exit is itself a commentary on the transition’s design philosophy: the legal world of sickness was not to be continued by other means, even administratively. That distinction was challenged in court within months, and the challenge produced the repeal’s most important judgment.

One feature of the window in the second class deserves a moment’s attention, because it determined what the successor tribunal actually received. A reference made under the Code by a company whose sickness proceedings had abated was not a continuation of the old case under a new name. It was a fresh application under a statute with a different trigger, which the company, or a creditor acting independently, had to frame as a case of default, to be tested on the Code’s terms by a tribunal that owed nothing to the Board’s findings, its inquiries or its draft schemes. Companies that had spent years assembling a record of erosion, sacrifice and negotiation before the Board found that the record carried persuasive weight at most: the factual history of their decline could inform the new process, but the legal entitlements built on that history, the stay, the deemed consents, the Board’s protective directions, had abated with the proceedings that created them. The one hundred and eighty days therefore functioned less as a bridge than as a starting gun, and the tribunal’s earliest corporate docket included, alongside genuinely new defaults, the distilled residue of the sickness era: the companies for whom two decades of supervised rescue had produced neither revival nor burial, presented at last to a forum instructed to decide.

The fairness question: abatement before the Delhi High Court

The petitioners in the Delhi High Court litigation, Ashapura Minechem Ltd and ATV Projects (India) Ltd among them, in W.P.(C) 4340 of 2017 and its companion petitions, attacked substituted Section 4(b) as arbitrary and discriminatory, and their grievance was concrete rather than theoretical. ATV Projects had been declared sick in 1999. IDBI had been appointed its operating agency, a scheme had been formulated over years of proceedings, modified, and reached an advanced stage of consideration, and then, on 1 December 2016, the entire proceeding abated by force of the commencement notification. Eighteen years of record, negotiation and partial agreement evaporated, and the company was directed to begin again before the National Company Law Tribunal within one hundred and eighty days, in a process in which the actors, the voting rules and the philosophy all differed. The petitioners argued that companies whose schemes had been sanctioned days earlier kept the benefit of their schemes under the savings, while companies whose schemes were days from sanction lost everything, and that a line drawn by the calendar rather than by any difference in merit violated the guarantee of equality in Article 14 of the Constitution.

A Division Bench of the Delhi High Court, Sanjiv Khanna and Pratibha M. Singh JJ., decided the petitions on 5 December 2017 and upheld Section 4(b). The Court’s reasoning repays attention because it states the constitutional theory on which large legislative transitions in India rest. The classification between cases where schemes had been sanctioned and cases where schemes were still pending was, the Court held, intelligible and not discriminatory: the two classes were differently situated, since one held a completed, binding instrument and the other held an expectation, and in any event both classes would be governed by the Code, including in respect of implementation, supervision and appeals connected with sanctioned schemes. There was no legitimate expectation of continuing to be governed by a repealed enactment when the legislature’s manifest intention was the complete replacement of the prior regime. And the petitioners were not left remediless: their course was to approach the National Company Law Tribunal within the stipulated period, and any question of condoning delay could be considered if permissible in law. The judgments in the batch, including the companion challenge by Meghdoot Projects Ltd, applied the same analysis.

The decision is defensible on its doctrine and still leaves a residue of unfairness that an honest assessment should record. Legislative transitions must draw lines somewhere, and a line between decided and undecided business is the most conventional line of all; every legal system that has replaced a forum mid-stream has drawn it there, and the alternative, carrying the old tribunal’s unfinished business into the new system wholesale, would have reproduced the sickness process inside the Code. But the cost of the line fell with unusual weight in this transition because of the old regime’s own delays. A company whose scheme was pending in 2016 after proceedings begun in 1999 was, in substantial part, a victim of the pace of the institution the State had required it to use. To tell that company that its eighteen years counted for nothing, because the State had replaced the institution, is to make the citizen bear the price of the State’s delay twice: once in the lost years, and again in the lost proceedings. The Court’s observation about condonation of delay was the system’s only acknowledgement of that weight, and it directed companies to the tribunal’s discretion rather than restoring anything by right. Nothing in this assessment of the transition rules is advice for any company in a comparable position, for the outcomes turned entirely on dates and on the class into which a particular case fell on the appointed day. As precedent, the case stands for a proposition larger than the sickness regime: when Parliament replaces an entire legal world, the Constitution permits it to close the old world’s files, and the equities of individual files, however strong, are arguments for transition design rather than grounds for striking the transition down. The lesson for drafters is therefore directed at the moment of repeal itself. Savings and windows are not drafting courtesies. They are the whole of the justice that a repeal does to the people caught inside it.

Commencement as a constitutional habit: why Indian repeals wait

The device that made the thirteen-year gap possible deserves its own examination, because the sickness repeal is an extreme instance of a general feature of Indian legislation. Indian Acts routinely provide that they shall come into force on a date the Central Government appoints by notification, and different dates may be appointed for different provisions. The device has honest uses: a statute creating institutions cannot sensibly commence before the institutions exist, tax and regulatory statutes need rules, forms and systems prepared, and phased commencement lets a large code be switched on in working order rather than as a paper proclamation. But the device as drafted carries no outer limit. Parliament decides that a law shall exist, delegates the question of when to the executive, and ordinarily imposes no deadline, no duty to report delay, and no consequence for silence. The Supreme Court has declined to fill that silence by direction, treating the choice of the appointed day as an executive function into which a mandamus will not run, even while benches have recorded their unease at provisions left uncommenced for years. The result is a recognised twilight category in Indian law: the enacted but unborn statute, present in the Gazette, citable as evidence of legislative intent, and wholly without legal effect.

Not all twilight statutes are waiting for the same thing, and the analytical point of this article’s central claim can be stated as a discipline for critics. Some Acts wait by choice: the government of the day prefers the announcement of the law to its operation, and commencement is withheld as a continuing political decision. Some wait by dependency: commencement is structurally impossible or irresponsible until machinery outside the Act, a tribunal, a regulator, a fund, a cadre, exists to receive its functions. Some wait by litigation: the machinery exists on paper but its legal validity is before the courts, and commencing the Act would build a jurisdiction on ground a judgment might remove. The three causes demand three different criticisms and three different remedies. Choice is answered politically, by pressure on the government that keeps choosing. Dependency is answered administratively, by building the missing institution, and its proper defendant is whichever government left the institution unbuilt. Litigation is answered in court and in redrafting, and its timeline is only partly within the state’s control. The sickness repeal passed through all three causes in sequence, which is what makes it the complete specimen of its kind: litigation from 2003 to 2010, dependency from 2010 until the tribunal’s constitution in 2016, and, interwoven throughout, a measure of choice, since no government treated the prerequisite as urgent until a comprehensive insolvency statute made the tribunal worth constituting for its own sake. A reader who asks of any stalled Indian reform only why the government did nothing has asked the least useful of the available questions. The better question is which of the three waits the statute is in, because the answer identifies who can end the wait, and how.

The sickness repeal also marks the outer limit of how long such a wait can run without the waiting itself becoming the scandal. Thirteen years approaches the working life of the institution being abolished: members appointed to the Board in the repeal’s shadow served, inquired and sanctioned schemes under a statute that Parliament had already voted to destroy, and companies entered the process in years when its termination had been enacted law for a decade. A legal system can absorb a commencement gap of a year or two as administrative prudence; a gap of thirteen years converts the gap into a governing fact, around which behaviour reorganises itself. Promoters filed references in the 2010s in the knowledge that the Board was condemned, calculating, in many cases correctly, that the condemned forum would outlast the proceedings they were starting. Creditors priced the shelter into their lending because the shelter, though repealed in the Gazette since 2004, was in force in every courtroom and every recovery office that mattered. The episode therefore teaches a drafting lesson sharper than the general one about dependencies. An uncommenced repeal is not a neutral pause in a statute’s life. It is a second statute, operating by expectation, and its effects on conduct begin from the day the expectation forms rather than the day the notification issues.

The thirteen-year repeal: a timeline of what was in force

The table below is the article’s findable artefact. Its third column is the one that matters: at every stage of the story it records what law was actually in force, which is the column in which the thirteen-year gap becomes visible as a legal fact rather than a rhetorical flourish.

Stage	Event	What was legally in force
1985	The sickness Act is enacted as Act 1 of 1986, on the Tiwari Committee’s recommendations	Winding up under the Companies Act 1956; no sickness regime yet commenced
12 January 1987 and 15 May 1987	The Act commences in two stages; the Board is established and becomes functional	The sickness Act governs references, inquiries, schemes and the Section 22 stay
1991	Government companies are brought within the Act	The sickness regime extends to public sector industrial companies
13 July 1993	The Goswami Committee reports, urging a default-based definition and fast-track winding up	The sickness Act continues unamended in its essentials
31 July 2000	The Eradi Committee reports, recommending repeal and merger into the Companies Act	The sickness Act continues; the Board’s record to 2000 shows 264 revivals in 3,068 references
2002	The Companies (Second Amendment) Act writes Sections 424A to 424L into the 1956 Act and creates the tribunal on paper	The amending provisions are never notified; the sickness Act remains the operative law
1 January 2004	Presidential assent to the Repeal Act, Act 1 of 2004, titled 2003	The Repeal Act exists but is uncommenced; the sickness Act remains in force
30 March 2004	The Madras High Court in R. Gandhi strikes at the tribunal design of 2002	The tribunal cannot be operationalised; abolition of the Board cannot be notified
2010	The Supreme Court in Union of India v. R. Gandhi upholds the tribunal subject to corrections	The sickness Act continues while the tribunal awaits a statutory home and appointments
2013	The Companies Act 2013 enacts Chapter XIX, Sections 253 to 269, on revival of sick companies	Chapter XIX is never notified; the sickness Act continues
1 June 2016	The National Company Law Tribunal is constituted under the 2013 Act	The sickness Act continues for its last months; the successor forum finally exists
1 November 2016	The Code, by Section 252 and the Eighth Schedule, substitutes Section 4(b) of the uncommenced Repeal Act	The sickness Act is still in force; the transition rule for its repeal is rewritten in advance
25 November 2016	Commencement notifications S.O. 3568(E) and its companion appoint the day	The sickness Act remains in force until the appointed day
1 December 2016	The Repeal Act commences; the Board and the Appellate Authority stand dissolved; pending proceedings abate	The Insolvency and Bankruptcy Code governs corporate distress; sanctioned schemes survive under its supervision
2017	The Removal of Difficulty Order, S.O. 1683(E), settles the treatment of sanctioned schemes; the Delhi High Court upholds Section 4(b) on 5 December 2017	The Code’s transition settlement is complete and constitutionally sustained

What the Code kept, discarded and added

Template accounts of the repeal often describe the Insolvency and Bankruptcy Code as the sickness Act’s opposite. The truth is more instructive: the Code is best understood as keeping the old regime’s furniture, discarding its theory of the patient, and adding the machinery of decision that the old regime never possessed. What it kept, first, was the moratorium itself. Section 14 of the Code imposes a stay on proceedings, execution and enforcement on admission, recognisably descended from Section 22, and the courts construing the Code’s stay have worked in a legal culture formed by the Section 22 cases, even while policing the new provision’s different text and purpose. It kept, second, the expert tribunal: the National Company Law Tribunal that Eradi wanted and the 2002 amendment designed is the Code’s adjudicating authority for companies, so the forum of the replacement is the very forum the sickness reformers demanded. It kept, third, the binding plan: a resolution plan approved by the committee of creditors binds the corporate debtor and its employees, members, creditors and guarantors, just as a sanctioned scheme bound the same constituencies under Section 18(8), because no collective restructuring law can function if every bound party needs its own signature. And it kept, fourth, revival as a legitimate and indeed preferred outcome: the Code’s first objective is resolution, and liquidation is its fallback, a direct inheritance from the sickness regime’s founding refusal to treat closure as the natural fate of a failing firm.

What the Code discarded was the theory. Gone is the balance-sheet definition of the patient, the five-year registration condition, the audited-accounts timetable and the category of potential sickness with its alarm bell attached to nothing. Gone is the debtor’s board as gatekeeper of the process, and with it the power to choose the moment of one’s own protection. Gone is the operating agency, the state-designated bank instructed to design the rescue of a borrower to whom it was itself exposed, and gone is the deemed consent of silent creditors as the engine of financial sacrifice. Gone, above all, is the indefinite: the old regime’s endeavour clauses and open implementation periods are replaced by a process with a statutory clock, and the stay’s legitimacy is tied to that clock rather than floating free of it.

What the Code added is the machinery of decision, and it is here that the contrast carries its real lesson. On admission, management of the corporate debtor vests in a regulated insolvency professional and the powers of the board stand suspended, so the question that the sickness regime treated as one discretionary measure among many, whether incumbents should run the company during its rescue, is answered by rule at the threshold. The creditors whose money is at risk sit as a committee and decide by vote between competing resolution plans or liquidation, replacing administrative judgement about viability with the judgement of the loss-bearers. A regulator, the Insolvency and Bankruptcy Board of India, and a licensed profession of insolvency practitioners stand behind the process, institutions the sickness regime never had. And Section 238’s overriding effect is coupled to a design that intends the Code to be, as the Supreme Court described it in Innoventive Industries Ltd v. ICICI Bank Ltd in 2017, a complete code on its subject, so that the contests the old regime lost to parallel statutes and parallel forums are settled in advance. Read against the sickness Act, the Code’s novelties are all addressed to a single diagnosis: the old law failed less because its aims were wrong than because nobody inside it was empowered, obliged and timed to decide. The new law is a machine for deciding.

Has the problem merely moved?

The most serious counter-reading of the repeal deserves a direct answer, because it is not frivolous. Critics of the successor regime observe that the National Company Law Tribunal has itself accumulated delays, that admission to the insolvency process can be contested for long periods before the moratorium even begins, and that the queue of companies in distress did not vanish with the Board’s dissolution; it changed buildings. On this account, repeal and replacement exchanged one slow tribunal for another, and the celebration of December 2016 confuses a change of signage with a change of substance. The observation about institutional capacity is fair and is borne out by the implementation record of the Code in its early years: tribunal benches are finite, insolvency litigation is inventive, and no statutory clock survives contact with a determined appellant unchanged. A legal system that spent thirteen years unable to constitute a tribunal should be humble about its ability to staff one to the level its statutes assume.

The counter-reading nevertheless misses the one change that alters the strategic structure of delay. Under the sickness regime, delay was an asset of the debtor: every month of pendency was a month of Section 22 protection enjoyed by promoters who remained in possession and in control, so the party with the greatest power to prolong the process was also the party who profited from prolonging it. Under the Code, admission transfers control to an insolvency professional and suspends the board, so delay after admission no longer pays the incumbent anything; the promoters’ interest runs the other way, toward a quick resolution that preserves whatever value their stake retains, and the creditor committee that controls the timetable bears the cost of its own slowness in the depreciation of the estate. Delay in the new system is a failure of capacity, deplorable and worth the criticism it receives. Delay in the old system was a strategy, available to the party the process existed to discipline. That is the difference the repeal actually made, and it is a difference in kind rather than in degree, even where the calendars of the two tribunals look uncomfortably alike.

The verdict on the repeal, then, is threefold. As an act of legislative hygiene it was unanswerable by 2003 and remains so: a statute whose definition admitted patients too late, whose stay rewarded the conduct it existed to correct, and whose tribunal’s own record refuted its premise had exhausted every defence except the political difficulty of replacement. As an act of transition it was thirteen years late for reasons that began in a genuine institutional dependency and ended in avoidable political delay, and its final settlement, abatement with a window for the undecided and survival for the decided, was orthodox in law and hard in individual cases in ways the Delhi High Court acknowledged but could not cure. And as a case study it leaves the series’ most transferable lesson. A repeal is not a decision; it is a dependency graph, and Parliament that votes to abolish an institution before securing the institution that replaces it has voted for the gap between the two, however little it intends the gap. The sickness Act’s strangest feature was never Section 22 or the Board’s record. It was that for thirteen years India had formally agreed, in an enacted and assented statute, that the regime should end, and the regime continued anyway, because the agreement had been recorded one institution too early.

What survived the repeal: the afterlife of the sickness regime

A repealed statute does not vanish from the law; it changes its mode of existence, from command to authority. The sickness Act’s afterlife has been unusually substantial, for three reasons. The first is that its case law remains the foundation on which Indian lawyers think about a statutory moratorium. The questions Section 22 litigated for thirty years are the questions every successor stay must answer: does a moratorium reach public dues, as Gram Panchayat held it did; does it catch enforcement dressed in another statute’s clothing, as Maharashtra Tubes held it did; where does it stop, as Shree Chamundi Mopeds stopped it at a landlord’s claim to possession; and does it protect anyone beyond the debtor, as Kailash Nath Agarwal held it did not protect guarantors. When the Insolvency and Bankruptcy Code’s Section 14 generated the same family of disputes, the courts answered them in a legal culture those decisions had formed, and in State Bank of India v. V. Ramakrishnan in 2018 the Supreme Court held, in the pattern Kailash Nath had set, that the Code’s moratorium does not extend to the property of a guarantor. The doctrine travelled even though the statute did not.

The second reason is that the regime’s own final judgment was about its ending. In Madras Petrochem Ltd v. Board for Industrial and Financial Reconstruction, decided in January 2016, the Supreme Court worked out the interaction between the sickness Act and the Securitisation Act and held that a reference abated where secured creditors representing not less than three-fourths in value of the outstanding debt had taken recovery measures under the Securitisation Act. Ten months before the repeal commenced, the old system’s highest court was thus engaged in defining the conditions of the old system’s dissolution, case by case, creditor majority by creditor majority. The judgment belongs in the repeal’s story as evidence that the shelter was being dismantled from inside the statute before Parliament’s replacement arrived, and it stands in the reports as the sickness jurisprudence’s last major word: a decision that a company’s protection ended when its secured creditors, by the statutory fraction, withdrew their patience.

The third reason is rhetorical, and in policy terms the most powerful. The Board for Industrial and Financial Reconstruction survives as the Indian insolvency debate’s standing cautionary example, the fate against which every new proposal is measured. Defenders of the Code’s deadlines invoke the Board’s open-ended inquiries; defenders of its transfer of control invoke the promoters who sat behind Section 22; critics of tribunal capacity are answered, and answer back, in the Board’s vocabulary. Even the Delhi High Court’s abatement judgment has an afterlife beyond its facts, as the clearest modern statement that a legislature replacing an entire regime may close the old regime’s unfinished files without violating equality, a proposition that will be cited in every future transition of comparable scale. Legislatures rarely achieve complete influence over a subject. The sickness regime achieved it negatively: it so thoroughly educated Indian lawmakers in what a distress regime must not do that its repeal, thirteen years delayed and constitutionally contested, may prove to be the least important of its contributions. The design of its successor is the monument.

The vocabulary outlived the statute as well. Indian commercial speech still calls a failing enterprise a sick unit thirty years after the phrase acquired its statutory meaning, and policy for smaller enterprises continued to borrow the regime’s early-warning instinct: frameworks for the revival and rehabilitation of micro and small enterprises adopted concepts of incipient sickness and early stress, an admission that the potentially sick idea of Chapter IV, the alarm bell attached to no engine, had been sound in conception even where the parent Act failed to give it machinery. What died in December 2016 was a particular institutional answer to industrial failure. The questions it had been invented to answer, how early the state should see distress coming, who should decide that a firm is beyond saving, and who pays for the years between failure and burial, remain the standing questions of Indian insolvency law, and every subsequent framework is an attempt to answer them without repeating the Board.

Frequently Asked Questions

Q: What did SICA and the BIFR set out to achieve?

The Sick Industrial Companies (Special Provisions) Act was enacted to secure the timely detection of sickness in industrial companies and the speedy determination, by a board of experts, of preventive, ameliorative, remedial and other measures for their revival. Its premise, declared in Section 2 by reference to Article 39 of the Constitution, was that industrial capacity and the employment it carried were community resources whose loss through disorderly failure the state should prevent where prevention was possible. The Board for Industrial and Financial Reconstruction, established in 1987, was the instrument: a specialised tribunal that would inquire into a sick company, commission a scheme from an operating agency for its reconstruction, sanction schemes binding on all stakeholders, and recommend winding up to the High Court only where revival was not practicable.

Q: Why was Section 22 of SICA controversial?

Section 22 suspended, except with the consent of the Board or the Appellate Authority, proceedings for winding up, execution, distress, the appointment of a receiver, and suits for the recovery of money or the enforcement of security against a company under inquiry or under a scheme. The controversy arose from the combination of three features. The stay began almost automatically when a reference was registered, an act the company’s own board controlled; it operated while the promoters whose management had produced the failure remained in possession; and it lasted as long as the Board’s proceedings lasted, which was frequently years. Critics in the banking system and the Goswami Committee argued that a moratorium designed to protect a rescue had become a shelter under which defaulters held their creditors at bay, while defenders answered that no restructuring is possible without a stay and that the fault lay in the open-ended process the stay served.

Q: When was SICA actually repealed?

The sickness Act was repealed with effect from 1 December 2016, not in 2003. Parliament had enacted the Sick Industrial Companies (Special Provisions) Repeal Act in 2003, and the President assented to it on 1 January 2004, making it Act 1 of 2004, but the Act contained its own commencement clause and no notification brought it into force for thirteen years. The Ministry of Finance issued the commencement notifications, S.O. 3568(E) and its companion, on 25 November 2016, appointing 1 December 2016 as the day. On that day the sickness Act stood repealed, the Board and the Appellate Authority stood dissolved, and the Insolvency and Bankruptcy Code’s corporate insolvency provisions took effect in parallel, so that the repeal and the succession happened simultaneously.

Q: Why did the SICA Repeal Act sit unnotified for thirteen years?

The principal reason was dependency, not oversight. Commencing the repeal would dissolve the Board and strand its pending references, sanctioned schemes and appeals, so commencement required a successor forum able to receive that jurisdiction. The intended successor, the National Company Law Tribunal, was designed in the Companies (Second Amendment) Act 2002, but the Madras High Court’s judgment in R. Gandhi in 2004 struck at that design, the Supreme Court settled the tribunal’s constitutional footing only in 2010, the tribunal’s statutory home moved to the Companies Act 2013, and the tribunal was finally constituted on 1 June 2016. Only then could the repeal be switched on, which occurred on 1 December 2016. Political delay in completing the tribunal after 2010 compounded the structural block, but without a constituted tribunal the notification could not responsibly have been issued at all.

Q: What happened to cases pending before the BIFR?

They abated. Section 252 of the Insolvency and Bankruptcy Code, through its Eighth Schedule, substituted Section 4(b) of the Repeal Act with effect from 1 November 2016, and the substituted provision declared that every appeal before the Appellate Authority, every reference made to the Board, and every inquiry or proceeding pending before either body immediately before the Repeal Act’s commencement stood abated. Abatement extinguished the proceeding without any decision on its merits, and every Section 22 stay dependent on pendency fell with it. The provision opened one door in compensation: a company whose matter had abated could make a reference to the National Company Law Tribunal under the Code within one hundred and eighty days from the Code’s commencement, and no fee was payable for such a reference. The Delhi High Court upheld this settlement against constitutional challenge in 2017.

Q: Did the BIFR ever revive a sick company?

Yes, though far less often than it disposed of cases in other ways. The Eradi Committee, compiling the Board’s record for 1987 to 2000, recorded 264 companies revived out of 3,068 references in that period, with a further 375 under negotiation for revival, against 741 recommended for winding up and 626 dismissed as not maintainable. Compilations from the Board’s case statistics to the end of 2007 put sanctioned revival schemes at 825 against 1,337 recommendations for winding up. Some sanctioned schemes restored companies to trading health, and the Board’s defenders point to those cases and to its clearing-house function in forcing creditors, governments and managements onto a single record. The proportions, however, were the heart of the case against the regime: after thirteen years of operation, outright revivals were a small minority of outcomes.

Q: How is the Insolvency and Bankruptcy Code different from SICA?

The differences are systematic. The sickness Act was triggered by a balance-sheet event, the complete erosion of net worth shown in audited accounts; the Code is triggered by a default in payment. Under the sickness Act the company’s own board ordinarily started the process and stayed in control behind the Section 22 stay; under the Code, financial creditors, operational creditors or the company may apply, and on admission the management vests in an insolvency resolution professional while the board’s powers stand suspended. The sickness process had no enforceable end date and aimed at a scheme prepared by an operating agency; the Code runs on a statutory clock, places the decision with a committee of creditors voting on resolution plans, and treats liquidation as a legitimate outcome. Both laws contain a moratorium and a binding collective plan, but the Code subordinates the stay to a timed, creditor-controlled process.

Q: What made a company a sick industrial company?

Section 3(1)(o) of the Act defined a sick industrial company as an industrial company, registered for not less than five years, which had at the end of any financial year accumulated losses equal to or exceeding its entire net worth, net worth being the sum of its paid-up capital and free reserves. The company also had to own an industrial undertaking in a scheduled industry under the Industries (Development and Regulation) Act 1951, and ancillary and small scale undertakings were excluded from the definition of an industrial undertaking. The test was purely one of balance-sheet erosion: a company that had not paid its creditors for years was not sick in law until its losses had consumed the whole of its shareholders’ funds.

Q: What was a potentially sick company under SICA?

Chapter IV of the Act created an early-warning category below full sickness. A potentially sick industrial company was one whose accumulated losses at the end of a financial year had resulted in the erosion of fifty per cent or more of its peak net worth during the immediately preceding four financial years. The company’s board was required to report the fact to the Board for Industrial and Financial Reconstruction within sixty days of the finalisation of its audited accounts and to place the erosion before a general meeting of shareholders, and government, the Reserve Bank, financial institutions and scheduled banks could also report a company they believed to be potentially sick. The category carried duties of disclosure but no stay, no inquiry and no scheme, which is why critics treated it as an alarm attached to no machinery: detection was mandated at the halfway point of decline, while every operative power of the Act waited for total erosion.

Q: Who could make a reference to the BIFR apart from the company’s own board?

Section 15(2) of the Act gave the power to six public actors: the Central Government, the Reserve Bank of India, a state government, a public financial institution, a state level institution, or a scheduled bank, any of which could refer a company to the Board if it had sufficient reason to believe that the company had become a sick industrial company. The design assumed that the institutions financing industry would act as sentries, bringing failing companies into the regime when the companies’ own boards delayed. In practice the overwhelming pattern was the self-reference by the board of directors under Section 15(1), made within sixty days of the audited accounts that disclosed complete erosion of net worth. Because the filing of a reference triggered the Section 22 stay on registration, the dominance of the self-reference meant that the timing of the shelter was largely chosen by the party the shelter protected.

Q: What was an operating agency, and what did it do?

An operating agency was a public financial institution, a scheduled bank or a state level institution specified by the Board under Section 2 read with the scheme provisions, and in practice it was usually one of the large term-lending institutions or banks already exposed to the sick company. When the Board concluded under Section 17 that a company could not revive on its own but that remedial measures were necessary in the public interest, it directed an operating agency to prepare a scheme, ordinarily within ninety days. The agency investigated the company’s affairs, consulted its creditors and prepared the rescue blueprint: financial reconstruction, change or takeover of management, amalgamation, sale or lease of undertakings, rationalisation of staff, or a combination of these. The Board then circulated the draft for objections, modified it if necessary and sanctioned it. The arrangement contained an evident tension, since the agency designing the sacrifices was frequently itself among the largest creditors asked to make them.

Q: Were government companies covered by SICA?

Not at first. As enacted in 1985, the definition of an industrial company excluded government companies, on the reasoning that enterprises owned by the state would be restructured by the state through administrative action rather than through a statutory tribunal. That exclusion was removed by an amendment in 1991, and from then on government companies that met the definition of sickness, an industrial company registered for not less than five years whose accumulated losses equalled or exceeded its net worth, fell within the Act like private companies. The change mattered because public sector industrial units accounted for a large share of the economy’s accumulated sickness by the early 1990s, and their exclusion had left the largest single class of failing industrial employers outside the only restructuring forum the law provided. Their inclusion enlarged both the Board’s caseload and the reach of the Section 22 stay.

Q: Did the Section 22 stay protect a sick company’s guarantors?

No. In Kailash Nath Agarwal v. Pradeshiya Industrial and Investment Corporation of U.P. Ltd, decided in 2003, the Supreme Court held that the bar in Section 22 protected the sick company and its assets, and did not extend to proceedings against a guarantor who had guaranteed the company’s loans. The Court reasoned that the stay existed to protect the revival process and the property against which revival would be worked out, and that a guarantor’s liability was independent of the company’s, so a lender could proceed against the guarantor even while every remedy against the company itself was frozen. The ruling was significant for lenders in an otherwise airless regime, because the guarantee of promoters or third parties was frequently the only enforceable obligation left once a reference had been filed. It also confirmed the structure of the section: the shelter was personal to the sick company, however complete it was while it lasted.

Q: What happened to schemes that the BIFR had already sanctioned when the repeal took effect?

Sanctioned schemes survived the repeal, unlike pending proceedings. Section 5 of the Repeal Act contained the savings that protected them, and a Removal of Difficulty Order issued in 2017, S.O. 1683(E), amended Section 4(b) to settle their administration expressly: the implementation and supervision of a scheme sanctioned by the Board would be carried on under the Insolvency and Bankruptcy Code before the National Company Law Tribunal, and appeals in such matters would lie to the National Company Law Appellate Tribunal within ninety days. The Delhi High Court, in upholding Section 4(b), treated this distinction as the transition’s organising line, between business the old tribunal had completed, which the legal system carried forward, and business still in argument, which abated. A company operating under a sanctioned scheme therefore kept its scheme, its obligations and its protections in substance, but answered for them to a new forum applying a new statute.

Q: What did the Goswami Committee recommend on industrial sickness?

The Committee on Industrial Sickness and Corporate Restructuring, chaired by Dr Omkar Goswami, was constituted in April 1993 and reported to the Ministry of Finance on 13 July 1993. It recommended redefining sickness around default and early erosion of net worth rather than complete erosion, so that intervention could begin while a company could still be saved; recasting the Board’s role away from sanctioning open-ended rehabilitation packages and toward facilitating negotiated restructuring; and correcting a structure under which, in the Committee’s words as later summarised, rehabilitation assistance indirectly rewarded inefficient and irresponsible entrepreneurs. It also recommended fast-track winding-up tribunals in Mumbai, Kolkata, Chennai, Delhi and Bangalore, so that exit would be a credible alternative to rescue. The report influenced every later reform discussion, including the Eradi Committee and the drafting of the Insolvency and Bankruptcy Code, but its central recommendations were not implemented in the sickness Act itself.

Q: How did the SARFAESI Act change what happened to a reference before the BIFR?

The Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act 2002 cut the first statutory hole in the Board’s monopoly. A proviso added to Section 15(1) of the sickness Act in 2002 provided that where secured creditors representing not less than three-fourths in value of the amounts outstanding against a company had taken measures to recover their secured debt under Section 13(4) of the Securitisation Act, the reference before the Board would abate. The Supreme Court confirmed the working of that proviso in Madras Petrochem Ltd v. Board for Industrial and Financial Reconstruction in 2016: once the three-fourths threshold of secured creditors had acted under the Securitisation Act, the sickness proceedings came to an end and the Section 22 protection fell with them. For the first time, a qualified majority of secured lenders could, by their own enforcement choice, dissolve the shelter that a reference had created.

Q: How many cases did the BIFR decide, and how did most of them end?

The Board’s caseload is best stated through the Eradi Committee’s compilation of its record for 1987 to 2000: 3,068 cases were referred in that period, of which all but 1,062 had been disposed of, with 264 companies revived, 375 under negotiation for revival, 741 recommended for winding up and 626 dismissed as not maintainable. Compilations from the Board’s own case statistics extend the picture to the end of 2007, by which time registered references had reached 5,471, sanctioned revival schemes 825, and recommendations for winding up 1,337. The distribution tells the regime’s story in one view: winding up was recommended roughly five times as often as revival was achieved in the Eradi period, a fifth of references were dismissed as not maintainable at all, and the stock of undecided cases remained above a thousand. Disposal, in other words, usually meant an ending other than the rescue the statute was built to deliver.

Q: Could the BIFR punish promoters who had diverted a sick company’s funds?

Section 24 armed the Board against misfeasance. Where it was satisfied, on a report by the operating agency, that any person who had taken part in the promotion, formation or management of the sick company had been guilty of misfeasance, had diverted the company’s funds, or had managed its affairs in a manner highly detrimental to the company or the public interest, the Board could direct that person to repay or restore the money or property, or to contribute a sum to the company’s assets by way of compensation. Section 24(2) added a professional disqualification in substance: the Board could direct that no scheduled bank or identified institution provide financial assistance to such a person for ten years, after giving the person an opportunity of being heard. The powers were real but slow and infrequently used relative to the caseload, and they sat alongside the regime’s central anomaly: the same promoters exposed to Section 24 for past conduct retained possession of the company, behind the Section 22 stay, while the inquiry into that conduct proceeded.

Q: Why did employment politics keep the sickness regime alive for so long?

Because the alternative to the regime was visible unemployment, and it was concentrated. A large sick mill or plant was typically the dominant employer of its town, and its closure threw thousands of workers out of employment in a single district at a single moment, while the fiscal cost of keeping it nominally alive was dispersed across banks, suppliers and taxpayers and could be deferred indefinitely. Governments therefore preferred a process whose default outcome was continuation, and the sickness Act supplied exactly that preference with legal machinery: a tribunal directed to prefer revival, a stay that prevented any creditor from forcing the issue, and no deadline by which the question had to be answered. The industrial disputes law compounded the politics, since closure of larger establishments depended on government permission that was rarely forthcoming. Critics of the regime argued that this protection of jobs in failing firms was bought at the price of jobs in viable ones, whose credit the frozen banking system could not supply, but that cost was invisible and spread out, and the regime survived for as long as the political arithmetic favoured the visible saving.

Q: What was the Appellate Authority, and where did appeals from the BIFR go?

The Appellate Authority for Industrial and Financial Reconstruction, constituted under Section 5 of the Act in 1987, was the appellate tier of the sickness regime. Its chairman was required to be or to have been a judge of the Supreme Court, or a judge of a High Court of not less than five years’ standing, and it sat with not more than three other members. Under Section 25, any person aggrieved by an order of the Board could appeal to the Appellate Authority within forty-five days of the order being issued. The two bodies together formed a closed appellate world: Section 26 barred civil courts from entertaining matters within their competence and prohibited injunctions against their proceedings, so challenge beyond the Appellate Authority lay only through the constitutional writ jurisdiction of the High Courts, and the pendency of an appeal itself attracted the Section 22 stay. Both bodies stood dissolved on 1 December 2016.